Cutler Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Cutler Group’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,500	Closed	-$5K	–	7749
2017 Q1	$5K	Buy	+2,500	New	+$22K	﹤0.01%	4836
2016 Q4	–	Sell	-11,400	Closed	-$8K	–	8046
2016 Q3	$8K	Buy	+11,400	New	+$133K	﹤0.01%	4541
2016 Q1	–	Sell	-300	Closed	-$1K	–	7945
2015 Q4	$1K	Buy	+300	New	+$6.15K	﹤0.01%	6298

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Cutler Group's OMED Position: Q2 2018 in Review

Cutler Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 856 shares — an estimated $2K sold.

Cutler Group first reported a position in OMED in Q4 2015 and held it in 6 quarters. The position peaked at $182K in Q4 2015. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

Cutler Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Cutler Group sold 856 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $2K.
Cutler Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Cutler Group's OncoMed Pharmaceuticals, Inc. position peaked at $182K in Q4 2015.
63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.